Saturday 17 October 2026
Export CRL’s income statement to Excel — free account
Charles River Laboratories International, Inc.
CRL Healthcare Diagnostics & Research
Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024. In the quarter to June 2026, revenue fell 2.72%, EPS fell 102.8%, free cash flow fell 12.2% and total debt rose 12.3%, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
299.77
6.47
−2.11%
Follow CRL
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(2.48%) | (4.35%) | (6.01%) | (7.69%) | |
Piotroski F-Score |
4 | 5 | 4 | 5 | |
| (1.15%) | (1.97%) | (2.41%) | (3.16%) | ||
ROIC |
1.63% | 0.31% | 0.81% | 1.07% | |
Return on Tangible Assets |
(4.45%) | (7.28%) | (9.69%) | (12.62%) | |
Average Days of Receivables |
66.63 | 64.44 | 63.47 | 64.96 | |
Free Cash Flow per Share |
11.05 | 10.46 | 7.99 | 7.72 | |
Free Cash Flow |
543.67 | 518.49 | 391.29 | 370.61 | |
Capital Expenditures |
(205.82) | (219.15) | (215.74) | (211.54) | |
| Other line items | |||||
Cash ROIC |
9.37% | 9.39% | 6.74% | 6.55% | |
Accounts Receivable Turnover |
5.41 | 5.62 | 5.53 | 5.41 | |
Accounts Payable Turnover |
17.84 | 18.62 | 19.25 | 18.78 | |
Inventory Turnover |
8.54 | 9.32 | 8.39 | 8.60 | |
Average Days of Payables |
22.71 | 20.17 | 17.93 | 19.11 | |
Days of Inventory on Hand |
40.51 | 40.55 | 48.15 | 46.94 | |
Tax Rate |
2.59 | 0.43 | 0.11 | 0.29 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
18.46% | 18.51% | 18.00% | 19.06% | |
Share Based Compensation of Revenue |
1.76% | 1.77% | 1.99% | 2.08% | |
Interest Coverage |
1.26 | 0.24 | 0.66 | 0.85 | |
Operating CF/Net income |
(8.41) | (5.11) | (3.29) | (2.44) | |
Depreciation/Fixed assets |
0.40 | 0.34 | 0.34 | 0.31 | |
Capex/Depreciation |
(0.32) | (0.39) | (0.42) | (0.46) | |
Revenue per Share |
81.76 | 81.01 | 82.27 | 83.28 | |
Operating CF per Share |
15.23 | 14.88 | 12.40 | 12.12 | |
Capex per Share |
(4.18) | (4.42) | (4.41) | (4.41) | |
Capex to Sales |
0.05 | 0.05 | 0.05 | 0.05 |
Columns are period end dates